REST is a novel prognostic factor and therapeutic target for medulloblastoma

Molecular Cancer Therapeutics

Volumn 11, Issue 8, 2012, Pages 1713-1723

  Taylor, Pete ^a   Fangusaro, Jason ^b   Rajaram, Veena ^b   Goldman, Stewart ^b   Helenowski, Irene B ^b   MacDonald, Tobey ^c   Hasselblatt, Martin ^d   Riedemann, Lars ^d   Laureano, Alvaro ^a   Cooper, Laurence ^a   Gopalakrishnan, Vidya ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; ENTINOSTAT; HISTONE DEACETYLASE; PROTEASOME; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR REST; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CHILD; DRUG TARGETING; EVENT FREE SURVIVAL; FEMALE; GENE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; NERVOUS SYSTEM DEVELOPMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SCHOOL CHILD; SYN1 GENE; TRANSCRIPTION REGULATION;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MALE; MEDULLOBLASTOMA; PROGNOSIS; REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC;

EID: 84864880240     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0990     Document Type: Article

References (50)

1. Fangusaro J, Chi S. Introduction to a special issue on pediatric neurooncology. J Child Neurol 2009;24:1341-2.
2. Dhall G. Medulloblastoma. J Child Neurol 2009;24:1418-30.
3. Castellino RC, De Bortoli M, Lu X, Moon SH, Nguyen TA, Shepard MA, et al. Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neurooncol 2008;86:245-56.
4. Crawford JR, MacDonald TJ, Packer RJ. Medulloblastoma in childhood: new biological advances. Lancet Neurol 2007;6:1073-85. (Pubitemid 350116703)
5. Eberhart CG, Kratz J, Wang Y, Summers K, Stearns D, Cohen K, et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 2004;63:441-9. (Pubitemid 38669665)
6. Suliman BA, Xu D, Williams BR. HDACi: molecular mechanisms and therapeutic implications in the innate immune system. Immunol Cell Biol 2012;90:23-32.
7. Jakacki RI. Treatment strategies for high-risk medulloblastoma and supratentorial primitive neuroectodermal tumors. Review of the literature. J Neurosurg 2005;102:44-52. (Pubitemid 44955009)
8. Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006;24:4202-8. (Pubitemid 46622300)
9. Bakst RL, Dunkel IJ, Gilheeney S, Khakoo Y, Becher O, Souweidane MM, et al. Reirradiation for recurrent medulloblastoma. Cancer 2011;117:4977 -82.
10. Gajjar A, Pizer B. Role of high-dose chemotherapy for recurrent medulloblastoma and other CNS primitive neuroectodermal tumors. Pediatr Blood Cancer 2010;54:649-51.
11. Gilbertson RJ. Finding the perfect partner for medulloblastoma prognostication. J Clin Oncol 2011;29:3841 -2.
12. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 2008;3:e3088.
13. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011;29:1408-14.
14. Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 2009;27:1627-36.
15. Schwalbe EC, Lindsey JC, Straughton D, Hogg TL, Cole M, Megahed H, et al. Rapid diagnosis of medulloblastoma molecular subgroups. Clin Cancer Res 2011;17:1883-94.
16. Carlotti CG Jr, Smith C, Rutka JT. The molecular genetics of medulloblastoma: an assessment of new therapeutic targets. Neurosurg Rev 2008;31:359- 68; discussion 368-9.
17. de Bont JM, Packer RJ, Michiels EM, den Boer ML, Pieters R. Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective. Neuro Oncol 2008;10:1040- 60.
18. Guessous F, Li Y, Abounader R. Signaling pathways in medulloblastoma. J Cell Physiol 2008;217:577-83.
19. Chong JA, Tapia-Ramirez J, Kim S, Toledo-Aral JJ, Zheng Y, Boutros MC, et al. REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons. Cell 1995;80:949-57.
20. Lonnerberg P, Schoenherr CJ, Anderson DJ, Ibanez CF. Cell type-specific regulation of choline acetyltransferase gene expression. Role of the neuron-restrictive silencer element and cholinergic-specific enhancer sequences. J Biol Chem 1996;271: 33358 -65.
21. Schoenherr CJ, Anderson DJ. The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes. Science 1995;267:1360-3.
22. Schoenherr CJ, Paquette AJ, Anderson DJ. Identification of potential target genes for the neuron-restrictive silencer factor. Proc Natl Acad Sci U S A 1996;93:9881-6. (Pubitemid 26296703)
23. Lawinger P, Venugopal R, Guo ZS, Immaneni A, Sengupta D, Lu W, et al. The neuronal repressor REST/NRSF is an essential regulator in medulloblastoma cells. Nat Med 2000;6:826 -31.
24. Su X, Gopalakrishnan V, Stearns D, Aldape K, Lang FF, Fuller G, et al. Abnormal expression of REST/NRSF and Myc in neural stem/progenitor cells causes cerebellar tumors by blocking neuronal differentiation. Mol Cell Biol 2006;26:1666-78.
25. Battaglioli E, Andres ME, Rose DW, Chenoweth JG, Rosenfeld MG, Anderson ME, et al. REST repression of neuronal genes requires components of the hSWI.SNF complex. J Biol Chem 2002;277:41038-45. (Pubitemid 35215694)
26. Ferreira A, Rapoport M. The synapsins: beyond the regulation of neurotransmitter release. Cell Mol Life Sci 2002;59:589-95. (Pubitemid 34457537)
27. Hallahan AR, Pritchard JI, Hansen S, Benson M, Stoeck J, Hatton BA, et al. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res 2004;64:7794- 800.
28. National Center for Biotechnology Information. PubChem Compound Database. [cited 2012 Mar 5 ]. Available from: http://pubchem.ncbi. nlm.nih.gov/summary/ summary.cgicid4261; http://pubchem.ncbi. nlm.nih.gov/summary/summary. cgicid444732; http://pubchem.ncbi. nlm.nih.gov/summary/summary.cgicid3221; http://pubchem.ncbi. nlm.nih.gov/summary/summary.cgicid5311.
29. Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010;6:238 -43.
30. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007;25:84-90. (Pubitemid 46087907)
31. Rikiishi H. Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol 2011;2011:830260.
32. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26:5541-52. (Pubitemid 47255934)
33. Das CM, Zage PE, Taylor P, Aguilera D, Wolff JE, Lee D, et al. Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines. Eur J Cancer 2010;46:2771-80.
34. Singh A, Rokes C, Gireud M, Fletcher S, Baumgartner J, Fuller G, et al. Retinoic acid induces REST degradation and neuronal differentiation by modulating the expression of SCF(beta-TRCP) in neuroblastoma cells. Cancer. 2011;117:5189-202.
35. Aguilera DG, Das CM, Sinnappah-Kang ND, Joyce C, Taylor PH, Wen S, et al. Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL. J Neurooncol 2009; 93:303- 18.
36. Gopalakrishnan V. REST and the RESTless: in stem cells and beyond. Future Neurol 2009;4:317-29.
37. Ooi L, Wood IC. Chromatin crosstalk in development and disease: lessons from REST. Nat Rev Genet 2007;8:544-54. (Pubitemid 46955208)
38. Furchert SE, Lanvers-Kaminsky C, Juurgens H, Jung M, Loidl A, Fruhwald MC. Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 2007;120:1787-94. (Pubitemid 46399367)
39. Huang Z, Wu Q, Guryanova OA, Cheng L, Shou W, Rich JN, et al. Deubiquitylase HAUSP stabilizes REST and promotes maintenance of neural progenitor cells. Nat Cell Biol 2011;13:142-52.
40. Westbrook TF, Hu G, Ang XL, Mulligan P, Pavlova NN, Liang A, et al. SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature 2008;452: 370 -4.
41. Weis DC, Visco DP Jr, Faulon JL. Data mining PubChem using a support vector machine with the Signature molecular descriptor: classification of factor XIa inhibitors. J Mol Graph Model 2008;27: 466-75.
42. Holthouse DJ, Dallas PB, Ford J, Fabian V, Murch AR, Watson M, et al. Classic and desmoplastic medulloblastoma: complete case reports and characterizations of two new cell lines. Neuropathology 2009;29: 398-409.
43. Leary SE, Zhou T, Holmes E, Geyer JR, Miller DC. Histology predicts a favorable outcome in young children with desmoplastic medulloblastoma: a report from the children's oncology group. Cancer 2011;117: 3262- 7.
44. Wu X, Northcott PA, Dubuc A, Dupuy AJ, Shih DJ, Witt H, et al. Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 2012;482:529-33.
45. Spiller SE, Ravanpay AC, Hahn AW, Olson JM. Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma. J Neurooncol 2006;79:259-70. (Pubitemid 44363729)
46. Hacker S, Dittrich A, Mohr A, Schweitzer T, Rutkowski S, Krauss J, et al. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene 2009;28: 3097 - 110.
47. Sonnemann J, Kumar KS, Heesch S, Muller C, Hartwig C, Maass M, et al. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. Int J Oncol 2006;28:755 -66.
48. Ballas N, Grunseich C, Lu DD, Speh JC, Mandel G. REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. Cell 2005;121:645-57. (Pubitemid 40720016)
49. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 2008;8:438-49. (Pubitemid 351744963)
50. Miller CP, Singh MM, Rivera-Del Valle N, Manton CA, Chandra J. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J Biomed Biotechnol 2011;2011:514261.